A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer (pages 1034–1041)
Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge E. Gomez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne and Vincent A. Miller
Article first published online: 28 JUL 2006 | DOI: 10.1002/cncr.22088
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent an important advance in the treatment of nonsmall cell lung carcinoma (NSCLC), but many patients who are treated with these agents do not benefit from their use. In an attempt to overcome resistance to EGFR tyrosine kinase inhibition, the authors of the current study administered high-dose, oral erlotinib on a weekly schedule to determine the safety and efficacy in patients with advanced NSCLC.